Does adiponectin benefit steatotic liver transplantation?

Liver Transplantation

Volumn 17, Issue 9, 2011, Pages 993-1004

  Elias Miro, Maria ^a   Massip Salcedo, Marta ^a,b   Jimenez Castro, Monica ^a   Peralta, Carmen ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ALPHA TOCOPHEROL; ATORVASTATIN; BETAINE; CANDESARTAN; CAVEOLIN 1; CYTOKINE; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; METFORMIN; OLMESARTAN; OXYNTOMODULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; RESVERATROL; RIMONABANT; ROSIGLITAZONE; S ADENOSYLMETHIONINE; SIBUTRAMINE; SMALL INTERFERING RNA; SPIRONOLACTONE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALSARTAN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CADAVER DONOR; DIABETES MELLITUS; DRUG EFFECT; DRUG MEGADOSE; DRUG TARGETING; FATTY LIVER; HORMONE ACTION; HUMAN; HYPERTENSION; LIVER FAILURE; LIVER INJURY; LIVER ISCHEMIA; LIVER REGENERATION; LIVER RESECTION; LIVER SURGERY; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ADIPONECTIN; ANIMALS; FATTY LIVER; HUMANS; INFLAMMATION; ISCHEMIA; LIVER; LIVER TRANSPLANTATION; MICE; MODELS, ANATOMIC; OBESITY; RATS; RATS, ZUCKER; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TISSUE AND ORGAN PROCUREMENT;

EID: 80051991685     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22358     Document Type: Review

References (113)

1. Massip-Salcedo M, Rosellõ-Catafau J, Prieto J, Avíla MA, Peralta C,. The response of the hepatocyte to ischemia. Liver Int 2007; 27: 6-16. (Pubitemid 46139423)
2. Casillas-Ramírez A, Mosbah IB, Ramalho F, Rosellõ-Catafau J, Peralta C,. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci 2006; 79: 1881-1894. (Pubitemid 44488610)
3. Selzner M, Clavien PA,. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113. (Pubitemid 32240490)
4. Peralta C, Rosellõ-Catafau J,. The future of fatty livers. J Hepatol 2004; 41: 149-151. (Pubitemid 39005167)
5. Busuttil RW, Tanaka K,. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651-663. (Pubitemid 36874450)
6. Wang Y, Zhou M, Lam KS, Xu A,. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol 2009; 53: 201-212.
7. Wang Y, Lam KS, Yau MH, Xu A,. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008; 409: 623-633. (Pubitemid 351214189)
8. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB,. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280.
9. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, et al. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 2006; 281: 16391-16400.
10. Massip-Salcedo M, Zaouali MA, Padrissa-Altés S, Casillas-Ramirez A, Rodés J, Rosellõ-Catafau J, Peralta C,. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. Hepatology 2008; 47: 461-472. (Pubitemid 351280714)
11. Wang Y, Xu LY, Lam KS, Lu G, Cooper GJ, Xu A,. Proteomic characterization of human serum proteins associated with the fat-derived hormone adiponectin. Proteomics 2006; 6: 3862-3870. (Pubitemid 44065163)
12. Tilg H, Hotamisligil GS,. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945. (Pubitemid 44307061)
13. Neumeier M, Hellerbrand C, Gäbele E, Buettner R, Bollheimer C, Weigert J, et al. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006; 12: 5490-5494. (Pubitemid 44501807)
14. Wolf AM, Wolf D, Avila MA, Moschen AR, Berasain C, Enrich B, et al. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol 2006; 44: 537-543. (Pubitemid 43227878)
15. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121. (Pubitemid 40007229)
16. Man K, Zhao Y, Xu A, Lo CM, Lam KS, Ng KT, et al. Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. Am J Transplant 2006; 6: 467-476. (Pubitemid 43382132)
17. Zaoualí MA, Reiter RJ, Padrissa-Altés S, Boncompagni E, García JJ, Ben Abnennebi H, et al. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res 2011; 50: 213-221.
18. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ,. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009; 2009: 831670.
19. Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A, et al. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 2009; 19: 467-474.
20. Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY,. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 233-237.
21. Kadowaki T, Yamauchi T,. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451. (Pubitemid 40686653)
22. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G,. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 679-683. (Pubitemid 43775007)
23. Baranova A, Gowder SJ, Schlauch K, Elariny H, Collantes R, Afendy A, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16: 1118-1125. (Pubitemid 44433145)
24. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-3504. (Pubitemid 41014319)
25. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA,. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935. (Pubitemid 32472900)
26. Rogers CQ, Ajmo JM, You M,. Adiponectin and alcoholic fatty liver disease. IUBMB Life 2008; 60: 790-797.
27. Zeng T, Xie KQ,. Ethanol and liver: recent advances in the mechanisms of ethanol-induced hepatosteatosis. Arch Toxicol 2009; 83: 1075-1081.
28. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ,. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100. (Pubitemid 38056380)
29. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G,. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-703. (Pubitemid 40006789)
30. Schäffler A, Schölmerich J, Büchler C,. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 273-280. (Pubitemid 40895403)
31. McCormack L, Dutkowski P, El-Badry AM, Clavien PA,. Liver transplantation using fatty livers: always feasible? J Hepatol 2011; 54: 1055-1062.
32. Silva MA,. Putting objectivity into assessment of steatosis. Transplantation 2009; 88: 620-621.
33. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-697.
34. Lo IJ, Lefkowitch JH, Feirt N, Alkofer B, Kin C, Samstein B, et al. Utility of liver allograft biopsy obtained at procurement. Liver Transpl 2008; 14: 639-646. (Pubitemid 351696275)
35. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E,. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010; 12: 365-383.
36. Czaja MJ,. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004; 40: 19-22. (Pubitemid 38868918)
37. Marra F, Bertolani C,. Adipokines in liver diseases. Hepatology 2009; 50: 957-969.
38. Mandal P, Roychowdhury S, Park PH, Pratt BT, Roger T, Nagy LE,. Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. J Immunol 2010; 185: 4928-4937.
39. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H,. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184. (Pubitemid 38868936)
40. Park PH, Thakur V, Pritchard MT, McMullen MR, Nagy LE,. Regulation of Kupffer cell activity during chronic ethanol exposure: role of adiponectin. J Gastroenterol Hepatol 2006; 21 (suppl 3): S30-S33. (Pubitemid 44266546)
41. Caraceni P, Domenicali M, Vendemiale G, Grattagliano I, Pertosa A, Nardo B, et al. The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. J Surg Res 2005; 124: 160-168. (Pubitemid 40463713)
42. Ben Mosbah I, Casillas-Ramírez A, Xaus C, Serafín A, Rosellõ-Catafau J, Peralta C. Trimetazidine: is it a promising drug for use in steatotic grafts? World J Gastroenterol 2006; 12: 908-914.
43. Caraceni P, Bianchi C, Domenicali M, Maria Pertosa A, Maiolini E, Parenti Castelli G, et al. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol 2004; 41: 82-88. (Pubitemid 39005157)
44. Chavin KD, Fiorini RN, Shafizadeh S, Cheng G, Wan C, Evans Z, et al. Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. Am J Transplant 2004; 4: 1440-1447. (Pubitemid 39159058)
45. Wan CD, Wang CY, Liu T, Cheng R, Wang HB,. Alleviation of ischemia/reperfusion injury in ob/ob mice by inhibiting UCP-2 expression in fatty liver. World J Gastroenterol 2008; 14: 590-594. (Pubitemid 351320826)
46. Uchino S, Yamaguchi Y, Furuhashi T, Wang FS, Zhang JL, Okabe K, et al. Steatotic liver allografts up-regulate UCP-2 expression and suffer necrosis in rats. J Surg Res 2004; 120: 73-82. (Pubitemid 38686532)
47. Ben Mosbah I, Alfany-Fernández I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis 2010; 1: e52.
48. Newmeyer DD, Ferguson-Miller S,. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003; 112: 481-490. (Pubitemid 36263081)
49. Alfany-Fernandez I, Casillas-Ramirez A, Bintanel-Morcillo M, Brosnihan KB, Ferrario CM, Serafin A, et al. Therapeutic targets in liver transplantation: angiotensin II in nonsteatotic grafts and angiotensin-(1-7) in steatotic grafts. Am J Transplant 2009; 9: 439-451.
50. Fernández L, Carrasco-Chaumel E, Serafín A, Xaus C, Grande L, Rimola A, et al. Is ischemic preconditioning a useful strategy in steatotic liver transplantation? Am J Transplant 2004; 4: 888-899. (Pubitemid 38745587)
51. Selzner M, Rüdiger HA, Sindram D, Madden J, Clavien PA,. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000; 32: 1280-1288.
52. Serafín A, Rosellõ-Catafau J, Prats N, Gelpí E, Rodés J, Peralta C,. Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. Hepatology 2004; 39: 688-698. (Pubitemid 38337648)
53. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H,. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-635. (Pubitemid 39221142)
54. Franco-Gou R, Peralta C, Massip-Salcedo M, Xaus C, Serafín A, Rosellõ-Catafau J,. Protection of reduced-size liver for transplantation. Am J Transplant 2004; 4: 1408-1420. (Pubitemid 39159055)
55. Fernández L, Heredia N, Grande L, Gõmez G, Rimola A, Marco A, et al. Preconditioning protects liver and lung damage in rat liver transplantation: role of xanthine/xanthine oxidase. Hepatology 2002; 36: 562-572. (Pubitemid 34977166)
56. Serafín A, Rosellõ-Catafau J, Prats N, Xaus C, Gelpí E, Peralta C,. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Pathol 2002; 161: 587-601. (Pubitemid 36142167)
57. Lehmann TG, Wheeler MD, Froh M, Schwabe RF, Bunzendahl H, Samulski RJ, et al. Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation 2003; 76: 28-37. (Pubitemid 36877111)
58. Soltys K, Dikdan G, Koneru B,. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2001; 34: 13-18. (Pubitemid 32591477)
59. Pratschke S, Angele MK, Grützner U, Tufman A, Bilzer M, Loehe F, et al. GSH attenuates organ injury and improves function after transplantation of fatty livers. Eur Surg Res 2010; 45: 13-19.
60. Nakano H, Nagasaki H, Barama A, Boudjema K, Jaeck D, Kumada K, et al. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. Hepatology 1997; 26: 670-678. (Pubitemid 27392359)
61. Gao W, Connor HD, Lemasters JJ, Mason RP, Thurman RG,. Primary nonfunction of fatty livers produced by alcohol is associated with a new, antioxidant-insensitive free radical species. Transplantation 1995; 59: 674-679.
62. Wheeler MD, Katuna M, Smutney OM, Froh M, Dikalova A, Mason RP, et al. Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther 2001; 12: 2167-2177. (Pubitemid 34081176)
63. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339. (Pubitemid 46376688)
64. Ramalho FS, Alfany-Fernandez I, Casillas-Ramirez A, Massip-Salcedo M, Serafín A, Rimola A, et al. Are angiotensin II receptor antagonists useful strategies in steatotic and nonsteatotic livers in conditions of partial hepatectomy under ischemia-reperfusion? J Pharmacol Exp Ther 2009; 329: 130-140.
65. Casillas-Ramirez A, Alfany-Fernandez I, Massip-Salcedo M, Juan ME, Planas JM, Serafin A, et al. Retinol-binding protein 4 and peroxisome proliferator-activated receptor-γ in steatotic liver transplantation. J Pharmacol Exp Ther 2011;338:143-153.
66. Seifalian AM, Piasecki C, Agarwal A, Davidson BR,. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999; 68: 780-784. (Pubitemid 29468195)
67. Teramoto K, Bowers JL, Kruskal JB, Clouse ME,. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 1993; 56: 1076-1082. (Pubitemid 23348677)
68. Ijaz S, Yang W, Winslet MC, Seifalian AM,. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10: 447-556.
69. Peralta C, Bulbena O, Bargallõ R, Prats N, Gelpí E, Rosellõ-Catafau J,. Strategies to modulate the deleterious effects of endothelin in hepatic ischemia-reperfusion. Transplantation 2000; 70: 1761-1770.
70. Yamada S, Iida T, Tabata T, Nomoto M, Kishikawa H, Kohno K, Eto S,. Alcoholic fatty liver differentially induces a neutrophil-chemokine and hepatic necrosis after ischemia-reperfusion in rat. Hepatology 2000; 32: 278-288. (Pubitemid 30614660)
71. Kahn D, Robson SC, Hickman R,. The effect of a tumour necrosis factor antibody on the regenerative response after partial hepatectomy in rats. Transpl Int 1994; 7 (suppl 1): S181-S182.
72. Yamada Y, Kirillova I, Peschon JJ, Fausto N,. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 1997; 94: 1441-1446. (Pubitemid 27087870)
73. Akerman P, Cote P, Yang SQ, McClain C, Nelson S, Bagby GJ, Diehl AM,. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992; 263 (pt 1): G579-G585.
74. Ellett JD, Evans ZP, Atkinson C, Schmidt MG, Schnellmann RG, Chavin KD,. Toll-like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury. Liver Transpl 2009; 15: 1101-1109.
75. Zhai Y, Shen XD, O'Connell R, Gao F, Lassman C, Busuttil RW, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173: 7115-7119. (Pubitemid 39628144)
76. Kang JW, Koh EJ, Lee SM,. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res 2011; 50: 403-411.
77. Massip-Salcedo M, Casillas-Ramirez A, Franco-Gou R, Bartrons R, Ben Mosbah I, Serafin A, et al. Heat shock proteins and mitogen-activated protein kinases in steatotic livers undergoing ischemia-reperfusion: some answers. Am J Pathol 2006; 168: 1474-1485.
78. Schmidt R,. Hepatic organ protection: from basic science to clinical practice. World J Gastroenterol 2010; 16: 6044-6045.
79. Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo M, Padrissa-Altés S, Bintanel-Morcillo M, Ramalho F, et al. Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury. Crit Care Med 2008; 36: 1256-1266. (Pubitemid 351482676)
80. Karatzas T, Olson L, Ciancio G, Burke GW III, Spires G, Cravero L, et al. Expanded liver donor age over 60 years for hepatic transplantation. Transplant Proc 1997; 29: 2830-2831. (Pubitemid 27481817)
81. Wang XH, Wang K, Zhang F, Li XC, Li J, De W, et al. Heme oxygenase-1 alleviates ischemia/reperfusion injury in aged liver. World J Gastroenterol 2005; 11: 690-694. (Pubitemid 40220759)
82. Shteyer E, Liao Y, Muglia LJ, Hruz PW, Rudnick DA,. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. Hepatology 2004; 40: 1322-1332. (Pubitemid 39657006)
83. Ezaki H, Yoshida Y, Saji Y, Takemura T, Fukushima J, Matsumoto H, et al. Delayed liver regeneration after partial hepatectomy in adiponectin knockout mice. Biochem Biophys Res Commun 2009; 378: 68-72.
84. Fernández MA, Albor C, Ingelmo-Torres M, Nixon SJ, Ferguson C, Kurzchalia T, et al. Caveolin-1 is essential for liver regeneration. Science 2006; 313: 1628-1632. (Pubitemid 44414035)
85. Walldorf J, Hillebrand C, Aurich H, Stock P, Hempel M, Ebensing S, et al. Propranolol impairs liver regeneration after partial hepatectomy in C57Bl/6-mice by transient attenuation of hepatic lipid accumulation and increased apoptosis. Scand J Gastroenterol 2010; 45: 468-476.
86. Gazit V, Weymann A, Hartman E, Finck BN, Hruz PW, Tzekov A, Rudnick DA,. Liver regeneration is impaired in lipodystrophic fatty liver dystrophy mice. Hepatology 2010; 52: 2109-2117.
87. Farrell GC,. Probing Prometheus: fat fueling the fire? Hepatology 2004; 40: 1252-1255. (Pubitemid 39656997)
88. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46: 122-129. (Pubitemid 47171928)
89. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al.; for SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
90. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307. (Pubitemid 44837778)
91. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006; 4: 1048-1052. (Pubitemid 44118842)
92. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al.; for LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008; 135: 100-110. (Pubitemid 351916703)
93. Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, et al. Bezafibrate regulates the expression and enzyme activity of 11beta- hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2007; 292: E1213-E1222. (Pubitemid 46536523)
94. Gõmez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R,. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-1647. (Pubitemid 43727474)
95. Esfandiari F, You M, Villanueva JA, Wong DH, French SW, Halsted CH,. S-Adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res 2007; 31: 1231-1239. (Pubitemid 46934391)
96. Song Z, Zhou Z, Deaciuc I, Chen T, McClain CJ,. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 2008; 47: 867-879. (Pubitemid 351449678)
97. Balmer ML, Siegrist K, Zimmermann A, Dufour JF,. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009; 29: 1184-1188.
98. Yamamoto E, Dong YF, Kataoka K, Yamashita T, Tokutomi Y, Matsuba S, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008; 52: 573-580.
99. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM,. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
100. Matsumoto S, Takebayashi K, Aso Y,. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006; 55: 1645-1652. (Pubitemid 44827131)
101. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395. (Pubitemid 41134267)
102. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA,. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49: 80-86.
103. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-153. (Pubitemid 46426854)
104. Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 1001-1008. (Pubitemid 43357772)
105. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81. (Pubitemid 36842239)
106. Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-268. (Pubitemid 46699517)
107. Zhang X, Li ZZ, Liu DF, Xu X, Mei ZC, Shen W,. Angiotensin-converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumour necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes. Clin Exp Pharmacol Physiol 2009; 36: 631-636.
108. Pagotto U, Vanuzzo D, Vicennati V, Pasquali R,. Pharmacological therapy of obesity [in Italian]. G Ital Cardiol (Rome) 2008; 9 (suppl 1): 83S-93S.
109. Textor SC, Canzanello VJ, Taler SJ, Schwartz L, Augustine J,. Hypertension after liver transplantation. Liver Transpl Surg 1995; 1 (suppl 1): 20-28.
110. Teoh NC, Williams J, Hartley J, Yu J, McCuskey RS, Farrell GC,. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury. Hepatology 2010; 51: 996-1006.
111. Reynaert H, Geerts A, Henrion J,. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther 2005; 22: 897-905. (Pubitemid 41634870)
112. Chojkier M,. Troglitazone and liver injury: in search of answers. Hepatology 2005; 41: 237-246.
113. Hassan-Khabbar S, Cottart CH, Wendum D, Vibert F, Clot JP, Savouret JF, et al. Postischemic treatment by trans-resveratrol in rat liver ischemia-reperfusion: a possible strategy in liver surgery. Liver Transpl 2008; 14: 451-459. (Pubitemid 351524400)